Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-6624 plus gemcitabine vs placebo plus gemcitabine in first-line metastatic pancreatic adenocarcinoma
2011-003753-26Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Dec 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of simtuzumab in pancreatic adenocarcinoma (PDAC), sponsored by Gilead Sciences. Started Dec 2011; status: terminated.
02
Drugs
simtuzumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2011-003753-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003753-26.